Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
NervGen Pharma Corp. Common stock
Market Cap
$143.84M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$143.60M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$143.10M
Net Profit Margin
-435.70%
TTM Avg
-1104.64%
3Y Avg
-1053.90%
5Y Avg
-4200.61%
Market Cap
$146.27M
Net Profit Margin
163.32%
TTM Avg
-34.49%
3Y Avg
-63.76%
5Y Avg
-75.19%
Market Cap
$146.28M
Net Profit Margin
-39.55%
TTM Avg
-86.23%
3Y Avg
-76.35%
5Y Avg
-60.08%
Market Cap
$146.62M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-85.02%
Market Cap
$139.84M
Net Profit Margin
-395.25%
TTM Avg
-276.53%
3Y Avg
-199.61%
5Y Avg
-174.03%
Market Cap
$139.47M
Net Profit Margin
-153.61%
TTM Avg
-101.12%
3Y Avg
-50.56%
5Y Avg
-33.71%
Market Cap
$148.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $143.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -435.70% | -1104.64% | -1053.90% | -4200.61% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 163.32% | -34.49% | -63.76% | -75.19% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -39.55% | -86.23% | -76.35% | -60.08% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | 0.00% | 0.00% | 0.00% | -85.02% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -395.25% | -276.53% | -199.61% | -174.03% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -153.61% | -101.12% | -50.56% | -33.71% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -312.63% | -188.89% | -109.57% | -101.19% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
